Navigation Links
QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
Date:1/4/2008

NEW YORK, Jan. 4 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Exchange-Traded Funds, a series of 20 underlying fund portfolios, today announced that effective at the opening of trading on Monday January 7, 2008, Alexion Pharmaceutical, Inc. (Nasdaq: ALXN) will replace Aspreva Pharmaceutical, Inc. (Nasdaq: ASPV) in the HealthShares(TM) Autoimmune-Inflammation Index. Alpharma, Inc. (NYSE: ALO) will also replace Aspreva Pharmaceutical, Inc. in the HealthShares(TM) Neuroscience Index. Aspreva Pharmaceutical is being acquired by Galencia Group (SWX: GALN). It was previously reported that Maxygen, Inc. would replace Asperva Pharmaceutical, Inc.

Companies included in the Autoimmune-Inflammation Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of inflammatory diseases such as osteoarthritis and autoimmune disorders including, but not limited to, rheumatoid arthritis, allergies, multiple sclerosis, psoriasis and lupus.

Companies included in the Neuroscience Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of neurological and psychiatric disorders including, but not limited to, Alzheimer's, Parkinson's, Huntington's, schizophrenia, anxiety, depression, epilepsy, pain and sleep disorders.

About HealthShares(TM)

XShares Advisors LLC, a financial services company based in New York, is the creator of the HealthShares(TM) family of Exchange Traded Funds (ETFs). HealthShares(TM) ETFs are organized into therapeutic 'Verticals' and represent specific areas of the healthcare, life science and biotechnology industries. Each Vertical addresses a distinct sub-segment of healthcare, such as the diagnosis and treatment of specific therapeutic areas (e.g. cardiology, cancer, infectious disease, etc.) and the development of medical devices (e.g. orthopedic repair, cardio devices, etc.). Each ETF tracks an index of 22-25 stocks and offers institutional and individual investors a more precise financial instrument that leverages the potential of healthcare investing while mitigating the risks of single stock picking. For more information, visit the company's website at: http://www.healthsharesinc.com.

About QED International Associates

QED International, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at http://www.qedinternational.com


'/>"/>
SOURCE QED International Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. Baxter International Fourth Quarter 2007 Financial Results Conference Call
3. Statement of International Dairy Foods Association President and CEO Connie Tipton
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
6. International Substance Detection Firm IDenta To Release New Lead Test Kit - Rash Of Toy Incidents Leads Company To Enter New Marketplace
7. International Human Rights Day Recognized by Terasem Movement, Inc.s Third Annual Colloquium on the Law of Transbeman Persons
8. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
9. Chambers Joins PRA International as Senior Vice President of Human Resources
10. Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
11. Natural Nutrition Launches International Marketing Campaign for New All Natural Analgesic: BLUE LIGHTNING(TM) Fast Pain Relief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
(Date:10/9/2017)... Jupiter, FL (PRWEB) , ... October 09, 2017 , ... ... episode, scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on ... Agriculture industry is faced with the challenge of how to continue to feed a ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
Breaking Biology Technology:
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):